MENU

PHAT Stock Phathom Pharmaceuticals (PHAT, $8.14) RSI Indicator left the oversold zone on December 16, 2024

A.I.dvisor
at Tickeron.com
Loading...
PHAT - Phathom Pharmaceuticals
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $8.14
Daily change: +$0.25 (+3.17%)
Daily volume: 1M
Capitalization: $556.6M
Industry: Biotechnology
This is a signal that PHAT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 29 similar cases where PHAT's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

PHAT in upward trend: price expected to rise as it breaks its lower Bollinger Band on December 12, 2024

PHAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where PHAT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PHAT's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for PHAT just turned positive on December 03, 2024. Looking at past instances where PHAT's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for PHAT crossed bearishly below the 50-day moving average on November 12, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PHAT entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). PHAT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (19.048) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Campus Drive
Phone
+1 877 742-8466
Employees
452
Web
https://www.phathompharma.com